Abstract:The present work aims to examine the worrying problem of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, which have now become really common in hospitals and risk hindering the global control of infectious diseases. After a careful examination of these phenomena and multiple mechanisms that make certain bacteria resistant to specific antibiotics that were originally effective in the treatment of infections caused by the same pathogens, possible strategies to stem antibiotic resistance are analyzed. This paper, therefore, focuses on the most promising new chemical compounds in the current pipeline active against multidrug-resistant organisms that are innovative compared to traditional antibiotics: Firstly, the main antibacterial agents in clinical development (Phase III) from 2017 to 2020 are listed (with special attention on the treatment of infections caused by the pathogens Neisseria gonorrhoeae, including multidrug-resistant isolates, and Clostridium difficile), and then the paper moves on to the new agents of pharmacological interest that have been approved during the same period. They include tetracycline derivatives (eravacycline), fourth generation fluoroquinolones (delafloxacin), new combinations between one β-lactam and one β-lactamase inhibitor (meropenem and vaborbactam), siderophore cephalosporins (cefiderocol), new aminoglycosides (plazomicin), and agents in development for treating drug-resistant TB (pretomanid). It concludes with the advantages that can result from the use of these compounds, also mentioning other approaches, still poorly developed, for combating antibiotic resistance: Nanoparticles delivery systems for antibiotics.

New class of antibiotics is a welcome discovery

A new class of antibiotics acts as molecular glue

A new type of antibiotic targets a drug-resistant bacterium

A novel antibiotic class targeting the lipopolysaccharide transporter

New β-lactam - Tetramic acid hybrids show promising antibacterial activities

Optimized Arylomycins Are a New Class of Gram-negative Antibiotics.

A New Class of Multi-Armed Antibiotics with Low Risk of Resistance

A new antibiotic selectively kills Gram-negative pathogens

Macrocyclic peptides: up-and-coming weapons to combat antimicrobial resistance

New antibacterial candidates against Acinetobacter baumannii discovered by in silico-driven chemogenomics repurposing

Discovery of Cationic Nonribosomal Peptides As Gram-negative Antibiotics Through Global Genome Mining

Recent Advances in Polypeptide Antibiotics Derived from Marine Microorganisms

New antibiotics from bacterial natural products

New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives

Tetracyclic Indolines As a Novel Class of Β-Lactam-selective Resistance-Modifying Agent for MRSA.

Rational design of a new antibiotic class for drug-resistant infections

Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant Gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane

A new antibiotic kills pathogens without detectable resistance

Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold

A new antibiotic from an uncultured bacterium binds to an immutable target

Clinical Crusade: Zosurabalpin's Charge Against Antibiotic Resistance